May 15, 2019 - These cancer drug developers could report market-moving news soon.
May 14, 2019 - Top Research Reports for Alphabet, Eli Lilly & CVS Health
May 14, 2019 - Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
May 05, 2019 - Teva's turnaround won't kick into high gear anytime soon.
May 03, 2019 - Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
May 03, 2019 - Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
May 02, 2019 - United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
May 01, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Apr 30, 2019 - LLY earnings call for the period ending March 31, 2019.
Apr 30, 2019 - Eli Lilly and Company (NYSE:LLY) Q1 2019 Results Earnings Conference Call April 30, 2019, 9:00 AM ET Company Participants Kevin Hern - Vice President, Investor Relations Dave Ricks - Chairman and CEO